Clinical Trial Update: Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating allogeneic NK cells (SMT-NK) with pembrolizumab in advanced biliary tract cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• SMT-NK

Snippet

Sponsor: SMT bio Co., Ltd. | Conditions: Biliary Tract Cancer | Phase 1, Phase 2 | Status: COMPLETED